Hantavirus Treatment: No Cure, But ECMO Cuts Mortality From 50% to 20%
Despite decades of research, hantavirus has no approved antiviral cure. Treatment is entirely supportive, which means the difference between survival and death depends on care quality more than any specific drug. The single most important intervention is ECMO, and access to it is the variable that explains most of the mortality variation between hospitals.
The treatment summary
For hantavirus pulmonary syndrome (HPS), the only established treatment is aggressive supportive care in an intensive care unit, with extracorporeal membrane oxygenation (ECMO) as the most impactful single intervention for severe cases. For hemorrhagic fever with renal syndrome (HFRS), supportive care plus dialysis when needed remains the standard, with some evidence for ribavirin benefit specifically in Hantaan and related Asian strains.
There is no antiviral drug approved for HPS. There is no vaccine in the United States or Europe. There is no specific therapy that targets the virus itself. Survival depends entirely on keeping the patient alive through the critical phase until the immune system clears the virus and the vascular leakage stops.
What ECMO actually does
Extracorporeal membrane oxygenation is a technique where blood is removed from the body, passed through a machine that adds oxygen and removes carbon dioxide, then returned to the body. The machine takes over the gas exchange function that the lungs normally perform.
For hantavirus, ECMO is critical because the primary lethal mechanism is non-cardiogenic pulmonary edema, which means fluid is leaking into the lungs from damaged capillaries. Conventional mechanical ventilation can struggle to maintain oxygenation when the lungs are full of fluid. ECMO bypasses the lungs entirely, giving the body time for the vascular leak to heal.
Published case series demonstrate the ECMO effect clearly. Pre-ECMO era mortality for severe Sin Nombre virus HPS was around 50 percent. Modern data from ECMO-capable centers shows mortality around 20 percent for severe cases that receive ECMO. The difference is the most dramatic mortality improvement available for any hantavirus treatment intervention.
The catch is that ECMO requires specific resources: trained perfusionists, specialized equipment, intensive monitoring capability, and the ability to safely transport unstable patients to ECMO-capable centers. In the US, ECMO is available primarily at large academic medical centers. In rural or community hospital settings, severe HPS cases must be transferred quickly, and the transfer itself is a critical risk window.
The fluid management problem
Hantavirus treatment also involves a counterintuitive fluid management approach that differs from standard severe respiratory illness care.
The instinctive response to a patient with low blood pressure and shock is aggressive fluid resuscitation. For most critical illness, this is correct. For hantavirus, aggressive fluid administration can worsen the pulmonary edema because the leaky capillaries shunt the administered fluid directly into the lungs.
The optimal approach is conservative fluid management combined with vasopressor support (drugs that constrict blood vessels and maintain blood pressure without adding volume). This requires the treating team to recognize that they are managing hantavirus rather than ordinary sepsis. If hantavirus is not on the differential diagnosis, standard sepsis protocols often involve fluid boluses that worsen outcomes.
This is one of several reasons why early diagnosis matters so much. A patient correctly identified as hantavirus receives different fluid management from a patient assumed to have bacterial sepsis or community-acquired pneumonia, even though the bedside presentation can look similar.
Why steroids are not used
Severe respiratory illness often gets corticosteroid therapy in modern ICU practice. COVID dexamethasone trials demonstrated significant mortality benefit for severe COVID. Steroids are also standard for various forms of acute respiratory distress syndrome.
For hantavirus, steroids are not recommended and can be harmful. The mechanism of vascular leak in hantavirus is not the same as in other forms of ARDS. Suppressing the immune response with steroids does not address the underlying problem and may interfere with the immune clearance that ultimately resolves the disease.
Published trials of methylprednisolone in HPS did not show benefit. Some series suggest possible harm. The current standard is to avoid steroids in HPS unless there is a separate indication.
This is another situation where misdiagnosis can be harmful. A patient with severe respiratory illness from undiagnosed hantavirus who receives empirical steroid therapy for presumed COVID or ARDS may have worse outcomes than they would have without steroids.
Ribavirin: works for HFRS, not HPS
Ribavirin is a broad-spectrum antiviral that has shown benefit in some viral hemorrhagic fevers. For HFRS caused by Hantaan virus, clinical trials in China and Korea have demonstrated mortality reduction when ribavirin is administered early in the course of disease. The drug is used in endemic Asian countries as standard care for severe HFRS.
For HPS, trials of ribavirin have not shown benefit. The reasons are debated but probably relate to differences in viral replication dynamics between the syndromes and the timing of treatment initiation. By the time HPS is diagnosed, the patient is often well past the window where ribavirin would be effective even theoretically.
The practical implication: ribavirin may be given for severe HFRS in Asian countries, but it is not indicated for HPS anywhere. The supportive care approach is the same regardless.
Antibody therapies in development
Research into specific antiviral therapies for hantavirus continues. The most advanced approach involves monoclonal antibodies that target the viral surface glycoproteins, neutralizing the virus before it can enter additional cells.
Several monoclonal antibody candidates have shown effectiveness in animal models for both HPS and HFRS strains. Early human trials are in progress for some candidates. None have yet reached approval for clinical use, but the trajectory is promising and the next 5-10 years may see the first specific antiviral therapy for hantavirus reach clinical practice.
Convalescent plasma (antibody-containing plasma from recovered hantavirus patients) has been used compassionately in severe cases, with some published reports suggesting benefit. The evidence base is limited, but the approach is sometimes considered when conventional supportive care is failing.
What happens day-by-day in an ICU
For a severe HPS case admitted to an ICU, the typical management trajectory looks roughly like this:
Day 1-2 (arrival in ICU): Establish airway, often through intubation. Conservative fluid management with vasopressor support for blood pressure. Continuous monitoring of oxygenation. Laboratory workup including hantavirus-specific testing. Cardiology evaluation if hemodynamic instability is severe.
Day 2-4 (peak severity): Mechanical ventilation with high oxygen and PEEP settings. If oxygenation cannot be maintained, ECMO consideration and transfer to ECMO-capable center if not already there. Continued vasopressor support. Possibly cardiac support medications.
Day 4-7 (cardiopulmonary peak): Most patients are at maximum support. ECMO running if needed. Renal function monitoring (kidneys can be affected in severe HPS even though HFRS is the kidney-specific syndrome). Nutritional support. Pressure ulcer prevention. DVT prophylaxis.
Day 7-14 (recovery phase): If the patient survives the cardiopulmonary peak, gradual improvement begins. ECMO can be weaned. Mechanical ventilation gradually reduced. Diuretic phase begins as the kidneys clear accumulated fluid. Patient may produce 4-6 liters of urine daily during this phase.
Day 14-21 (extubation and step-down): Most survivors are extubated during this window. Transfer from ICU to step-down or general ward. Begin physical therapy. Continued nutritional support and monitoring for complications.
Day 21-42 (discharge planning): Most survivors are discharged. Outpatient pulmonology follow-up. Gradual return to normal activity over 1-3 months. Some patients experience persistent fatigue or exercise intolerance for 6-12 months.
HFRS treatment differences
For HFRS caused by Hantaan, Puumala, or other Old World strains, the supportive care focus shifts from lungs to kidneys. Key differences:
- Dialysis may be required during the oliguric phase when patients produce little urine. Hemodialysis or continuous renal replacement therapy supports kidney function until recovery.
- Fluid management is similarly conservative but with different specific concerns. Volume overload is dangerous; hypovolemia is also dangerous. Daily fluid balance is closely monitored.
- Bleeding complications can occur with severe HFRS (Hantaan strain) and require attention to platelet function and coagulation. Hemorrhagic complications are less common with European strains.
- Hypertension often emerges during recovery and may persist long-term in some patients.
What this means for the public
For someone diagnosed with hantavirus or in a household where a confirmed case is being treated, several things are useful to know:
First, the treating team will not be giving the patient an antiviral cure. The supportive care is the treatment. This can be confusing when comparing to other severe illnesses where specific drugs are part of the plan.
Second, transfer to a higher-level center may be necessary for ECMO access. If a community hospital recommends transfer, this is not abandonment of care; it is the right intervention for severe HPS.
Third, the cardiopulmonary peak is brutal but time-limited. Patients who survive the first 7-10 days of severe disease often go on to full recovery, though the recovery itself is slow.
Fourth, the survival statistics for hantavirus reflect averages across a wide range of care quality. Patients at well-resourced centers with ECMO access have much better outcomes than the headline mortality rate suggests. Patients without ECMO access have worse outcomes.
The current treatment landscape is dominated by what is NOT available: no antiviral cure, no vaccine in the West, no specific therapy. What works is what works for many severe illnesses: skilled critical care, accurate diagnosis, appropriate technology, and time. For hantavirus, ECMO is the technology that has made the biggest difference, and improved physician awareness is the diagnostic factor that determines whether ECMO is brought to bear in time.